Antitrust matters are rarely isolated within a single state or federal agency or jurisdiction. We represent clients facing multi-dimensional antitrust challenges on the transactional, regulatory and litigation fronts, mobilizing an unmatched combination of courtroom excellence, government experience and legal, economic and academic prowess on our clients’ behalf.
Paul, Weiss secured a significant antitrust appellate victory for global medical technology company Becton Dickinson & Company (BD).
As reported in The Wall Street Journal, Bloomberg, Reuters and other media outlets, Paul, Weiss client Elanco U.S., Inc., a subsidiary of Paul, Weiss client Eli Lilly and Company, announced an agreement to acquire Boehringer Ingelheim Vetmedica, Inc.'s U.S. feline, canine and rabies vaccines portfolio, as well as a fully integrated manufacturing and R&D site, for $885 million.
A federal district court in Washington, D.C. rejected an application to preliminarily enjoin Paul, Weiss client Mastercard Incorporated from enforcing its ATM rules.
Paul, Weiss has been named Benchmark Litigation's "Antitrust Firm of the Year" for 2015. Litigation partners Aidan Synnott, Jacqueline Rubin and William Michael received the award for the firm on January 29 at the Essex House in New York at the second annual nationwide U.S. Benchmark Litigation Awards ceremony.
Less than a week after the U.S. Senate voted to approve a full slate of new commissioners to the Federal Trade Commission (FTC), four of those appointees were sworn in to their new positions.